AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) CEO Vincent J. Angotti purchased 15,000 shares of the stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average cost of $3.00 per share, with a total value of $45,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 15,000 shares of the company’s stock, valued at $45,000. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) traded down 0.84% during midday trading on Friday, reaching $2.95. The company’s stock had a trading volume of 1,136,886 shares. The company’s 50-day moving average price is $2.99 and its 200 day moving average price is $2.80. The firm’s market capitalization is $133.87 million. AcelRx Pharmaceuticals, Inc. has a 1-year low of $1.95 and a 1-year high of $4.08.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.01. AcelRx Pharmaceuticals had a negative net margin of 319.19% and a negative return on equity of 478.66%. The firm had revenue of $2.66 million for the quarter, compared to the consensus estimate of $2.63 million. On average, equities research analysts forecast that AcelRx Pharmaceuticals, Inc. will post ($1.13) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/27/acelrx-pharmaceuticals-inc-acrx-ceo-buys-45000-00-in-stock.html.

Institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. purchased a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $530,000. Virtu KCG Holdings LLC raised its position in shares of AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares in the last quarter. LMR Partners LLP purchased a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $319,000. WealthTrust Axiom LLC raised its position in shares of AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares in the last quarter. Hedge funds and other institutional investors own 30.37% of the company’s stock.

A number of brokerages have weighed in on ACRX. Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 1st. Roth Capital reiterated a “buy” rating and issued a $12.50 price objective on shares of AcelRx Pharmaceuticals in a research note on Thursday, August 10th. Zacks Investment Research upgraded AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Royal Bank Of Canada set a $6.00 price objective on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Friday. Finally, ValuEngine cut AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $7.50.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.